References
- YamanakaHSugiyamaNInoueETaniguchiAMomoharaSEstimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)Mod Rheumatol2014241334024261756
- SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnn Rheum Dis201069696497520444750
- CurtisJRSinghJAThe use of biologics in rheumatoid arthritis: current and emerging paradigms of careClin Ther200133667970721704234
- ListingJKekowJMangerBMortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximabAnn Rheum Dis201574241542124291654
- CramerJRoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
- BlumMAKooDDoshiJAMeasurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic reviewClin Ther201133790191321715007
- LyuRGovoniMDingQTreatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in GermanyRheumatol Int201636114315326314368
- ZinkAListingJKarySTreatment continuation in patients receiving biological agents or conventional DMARD therapyAnn Rheum Dis20056491274127915708884
- NeubauerSCifaldiMMittendorfTGanguliAWolffMZeidlerJBiologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in GermanyHealth Econ Rev2014413226208932
- CarmonaLGomez-ReinoJJBIOBADASER GroupSurvival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASERArthritis Res Ther200683R7216620398
- KievitWFransenJAdangEMLong-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring registerRheumatology201150119620321078625
- MarkatseliTEAlamanosYSaougouIVoulgariPVDrososAASurvival of TNF-alpha antagonists in rheumatoid arthritis: a long-term studyClin Exp Rheumatol2012301313822153557
- JobanputraPMaggsFDeemingAA randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 yearsBMJ Open201226e001395
- SvedbornADalenJLyuRTreatment persistence among patients with rheumatoid disease (RD) newly treated with subcutaneous TNF alpha blockersAnn Rheum Dis201574330
- SangiorgiDBenucciMNappiCPerroneVBudaSDegli EspostiLDrug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritisBiologics2015911912726604680
- Du PanSMDehlerSCiureaAZiswilerHRGabayCFinckhASwiss Clinical Quality Management PhysiciansComparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritisArthritis Rheum200961556056819405000
- FisherABassettKWrightJMBrookhartMAFreemanHDormuthCRComparative persistence of the TNF antagonists in rheumatoid arthritis – a population-based cohort studyPLoS One201498e10519325141123
- JohnstonSMcMorrowDFarrAJuneauPOgaleSComparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologicRheum Ther2015215971
- TangBRahmanMWatersHCCallegariPTreatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritisClin Ther20083071375138418691998
- BorahBHuangXZarotskyVGlobeDTrends in RA patients’ adherence to subcutaneous anti-TNF therapies and costsCurr Med Res Opin20092561365137719425902
- AgarwalSGlassRShadickNPredictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritisJ Rheumatol20083591737174418634159
- RamiroSLandewéRvan der HeijdeDHarrisonDCollierDMichaudKDiscontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non TNF inhibitors?RMD Open201511e00015526629366
- BaserOGanguliARoySXieLCifaldiMImpact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritisClin Ther20153771454146525999184
- ChoSKSungYKChoiCBBaeSCImpact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean national health insurance claims dataRheumatol Int201232123851385622193228
- KangJHParkDJLeeJWDrug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitisJ Korean Med Sci20142991205121125246737
- SakaiRTanakaMNankiTDrug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target moleculesAnn Rheum Dis201271111820182622504558
- SaokaewSSugimotoTKamaeIPratoomsootCChaiyakunaprukNHealthcare databases in Thailand and Japan: potential sources for health technology assessment researchPLoS One20151011e014199326560127
- WangKLiPChenLKatoKKobayashiMYamauchiKImpact of the Japanese diagnosis procedure combination-based payment system in JapanJ Med Syst20103419510020192060
- QuanHSundararajanVHalfonPCoding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative dataMed Care200543111130113916224307
- WuEChenLBirnbaumHYangECifaldiMRetrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritisCurr Med Res Opin20082482229224018577308
- YeawJBennerJSWaltJGSianSSmithDBComparing adherence and persistence across 6 chronic medication classesJ Manag Care Pharm200915972874019954264
- SinghJASaagKGBridgesSLJr2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritisArthritis Rheumatol201668112626545940
- LeePWaltJChiangTGuckianAKeenerJA gap analysis approach to assess patient persistence with glaucoma medicationAm J Ophthalmol2007144452052417692273
- OgaleSHitrayaEHenkHPatterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskelet Disord20111220421929807
- TanakaYTakeuchiTInoueERetrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)Mod Rheumatol200818214615218283523
- KoikeTHarigaiMInokumaSPostmarketing surveillance of the safety and effectiveness of etanercept in JapanJ Rheumatol200936589890619332630
- FewtrellMKennedyKSinghalAHow much loss to follow-up is acceptable in long-term randomised trials and prospective studies?Arch Dis Child20089345846118495909
- PetriHUrquhartJChanneling bias in the interpretation of drug effectsStat Med19911045775812057656
- ChiaLRSchlenkEADunbar-JacobJEffect of personal and cultural beliefs on medication adherence in the elderlyDrugs Aging200623319120216608375
- MatsubaraHKojimaTKanekoALong-term retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapyJ Rheumatol20144181583158925028370
- SalaffiFCarottiMDi CarloMFarahSGutierrezMAdherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritisJ Clin Rheumatol201521841942526587852
- BarbosaCDBalpMMKulichKGermainNRofailDA literature review to explore the link between treatment satisfaction and adherence, compliance, and persistencePatient Prefer Adherence20126394822272068
- MorganCMcBethJCordingleyLThe influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics eraRheumatology (Oxford)201554101780179125972390